CMPX shares slump after FDA recommends additional cancer trial
Compass Therapeutics shares fell more than 25% after the FDA recommended an additional trial for its lead cancer drug, potentially delaying commercialization.
S. Food and Drug Administration (FDA) recommended an additional trial for its lead cancer drug, potentially delaying the company’s path toward commercialization. At the time of writing, CMPX shares traded at their low…